Solid Tumors
A Phase 2, open-label, multicenter study to evaluate efficacy and safety of zanidatamab for the treatment of participants with previously treated HER2-expressing solid tumors (DiscovHER PAN-206) (JZP598-206)
- Details
ClinicalTrials.gov ID:
NCT06695845
Diagnosis Type:
NA
USOR Number:
- Address
,
P: